Diffuse Large B-Cell Lymphoma, NOS · Axicabtagene ciloleucel (axi-cel) CAR-T — single infusion after lymphodepletion
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-CAR-T-AXICEL |
| ID | IND-DLBCL-3L-AXICEL-CART |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 SRC-ZUMA-1-NEELAPU-2017 SRC-ZUMA-7-LOCKE-2022 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ option for r/r DLBCL. Ukraine access constraint is dominant barrier: international referral pathway (Israel / Poland / Germany / Spain) + USD 350-500K all-in cost. ZUMA-7 expansion to 2L for primary-refractory / early-relapse is a separate future Indication (IND-DLBCL-2L-CART-EARLYRELAPSE). Tisa-cel (Kymriah) and liso-cel (Breyanzi) alternative CD19 CAR-Ts — separate Regimen entities to add later.
Used By
Algorithms
ALGO-DLBCL-2L- ALGO-DLBCL-2LALGO-DLBCL-3L- ALGO-DLBCL-3L
Indication
IND-DLBCL-3L-LISO-CEL-CART- IND-DLBCL-3L-LISO-CEL-CART